Fei Ma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
6
6
1
N/A
0
3
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+5 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Tong Liu
The Second Affiliated Hospital of Harbin Medical University
Shared therapeutic areas:
Worked with same sponsors:
Ting Luo
West China Hospital
Shared therapeutic areas:
Worked with same sponsors:
Puma
Biotechnology
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
min yan
Henan Cancer Hospital
Shared therapeutic areas:
Worked with same sponsors:
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Melda Saglam, PhD
Hacettepe University
Shared therapeutic areas:
XiaoFeng Shen, MD
Nanjing Medical University
Shared therapeutic areas:
Alice P Chen, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
Study of ESG401 in Adults With Solid Tumors
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
All 6 trials loaded